Treatments administered following castration-resistant prostate cancer diagnosis while investigating the influence of prior treatment on the relationship between prostate-specific antigen kinetics and survival

This dataset comprises a single .docx file containing a single table of summary statistics for treatments administered to 295 patients for castration-resistant prostate cancer (CRPC). These treatments were administered as part of study to determine whether prostate-specific antigen (PSA) kinetics may serve as prognosticators regardless of prior local treatment.

The same patients were statified in two ways: i) their time to PSA nadir and ii) their time to CRPC progression. Treatments included Docetaxel, androgen receptor-axis targeted (ARAT) agent use, Cabazitaxel, Radium-233, and clinical trials. Data for the number of Docetaxel cycles are presented as median and interquartile range, while all other data are presented as numbers of participants and percentages of the total group.

The related study aims to determine the effect of prior local treatment and PSA kinetics during androgen-deprivation therapy (ADT) on the survival of CRPC patients. The authors performed a multicentre retrospective study which included patients who had been diagnosed with CRPC between September 2009 and November 2017, and investigated PSA kinetics during ADT, including percentage PSA decline, PSA nadir level, time to PSA nadir, and time to CRPC progression. Subgroup analysis was performed according to the prior history of local curative treatment.